About

This year, we showcased the latest innovations to overcome the field’s most pressing challenges of discovering more efficacious and symptom-specific targets, recapitulating psychiatric disorders in preclinical models, and mitigating placebo. Over 120 biotech and pharma scientists united at the 6th Annual Neuropsychiatric Drug Development Summit.

What Was New for 2023?

  • Dedicated spotlight on ‘precision neuropsychiatry’ with numerous case studies of how leading biopharma are innovating more targeted, symptom-driven approaches to treat patients experiencing a range of mental health disorders
  • 25+ brand-new speakers with expertise spanning neurobiology, medicinal chemistry, machine learning, and regulatory affairs, providing a comprehensive guide for revolutionizing neuropsychiatric therapeutics
  • Exploration of a greater range of therapeutic indications, with expansion into areas such as anorexia, PTSD, and autism spectrum disorder, in addition to psychiatric symptoms associated with neurodegenerative conditions

Attendees Joined Their Peers To:

Gilgamesh
AbbVie_logo.svg
Biogen_logo_logotype_symbol

Critically evaluate preclinical model systems to accelerate translational development of psychiatric drug candidates and explore beyond head twitch assays for detecting psychoplastogen activity with AbbVie, Gilgamesh Pharmaceuticals, and Biogen

delix-logo
Atai_Life_Sciences_logo
Tactogen

Debate the necessity of hallucinogenic properties for therapeutic action with Delix Therapeutics and uncover novel innovations to de-risk psychedelic candidates with Atai and Tactogen

stalicla_main_logo
Cybin
psilera
Jazz Pharmaceuticals

Collaboratively discuss key bottlenecks of psychedelic and non-psychedelic drug development with Cybin, Psilera, Jazz Pharmaceuticals, and STALICLA in the two-stream interactive workshop day

Otsuka_Holdings_logo.svg
Lundbeck.svg
MAPS logo

Gain key takeaways from companies already demonstrating significant success in the race to regulatory approval, with first-hand insights from Otsuka, MAPS PBC, and Lundbeck

Regeneron_logo.svg
National Institute of Mental Health

Discover the latest efforts to deepen understanding of biological and genetic drivers of psychiatric symptoms and translate into novel target discoveries with Regeneron, Entheos Labs, and National Institute of Mental Health

Who Did You Meet?

This meeting hosted CNS experts, from leading biopharma through to emerging start-ups, in one highly focused forum, with a shared goal of revolutionizing approaches to target and treat neuropsychiatric disorders.

Peers across discovery, translational, and clinical development had joined to crowd-source ideas and collaboratively define the next steps for advancing psychedelic and non-psychedelic therapeutic candidates through the clinic.

 “Great to have so many pharma experts reunited to discuss bottlenecks of neuropsychiatry R&D.”

External Innovation Manager, Boehringer Ingelheim

“Well-chosen speakers with late breaking presentations that were informative and helpful.” – Vice

President, Neuroscience, BioXcel Therapeutics

“The NPD summit is an exciting event that focuses on the current gaps & trends in Neuropsychiatric Drug Development”

Head of Neurocircuitry Modulation Biomarkers, Takeda

“This is a great forum for peer-to-peer connections and exchanges of ideas for anyone working in ALS”

Jeffrey Bornstein, Chief Medical Officer, Eledon Pharmaceuticals

“The speakers gave an insight into what companies are thinking vs most conferences that predominantly give an academic slant.”

Principal Scientist, Alkermes